Notch1 is a frequent mutational target in chemically induced lymphoma in mouse
Corresponding Author
Anneli Karlsson
Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
Fax: +461-322-1718
Linköping University, Department of Clinical and Experimental Medicine, S-58185 Linköping, SwedenSearch for more papers by this authorJonas Ungerbäck
Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
Search for more papers by this authorAnna Rasmussen
Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
Search for more papers by this authorJohn E. French
National Institute of Environmental Health Sciences, Laboratory of Molecular Toxicology, Research Triangle Park, NC
Search for more papers by this authorPeter Söderkvist
Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
Search for more papers by this authorCorresponding Author
Anneli Karlsson
Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
Fax: +461-322-1718
Linköping University, Department of Clinical and Experimental Medicine, S-58185 Linköping, SwedenSearch for more papers by this authorJonas Ungerbäck
Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
Search for more papers by this authorAnna Rasmussen
Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
Search for more papers by this authorJohn E. French
National Institute of Environmental Health Sciences, Laboratory of Molecular Toxicology, Research Triangle Park, NC
Search for more papers by this authorPeter Söderkvist
Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
Search for more papers by this authorAbstract
Activating Notch1 mutations have been reported in human T-lineage acute lymphoblastic leukemia (T-ALL) and lymphomas from genetically modified mice. We report that Notch1 is a prevalent and major mutational target in chemically induced mouse lymphoma. The regions of the gene that are frequently mutated are the heterodimerization domain and the N-terminal ligand-binding region, important for protein stability, and the polypeptide rich in proline, glutamate, serine and threonine (PEST) domains, which is critical for protein degradation. Another gene, CDC4, is also involved in Notch1 degradation and shows frequent mutations. Mutations in the heterodimerization and the ligand-binding regions may cause ligand-independent signaling, whereas mutations preventing protein degradation result in accumulation of intracellular Notch1. We analyzed 103 chemical-induced mouse lymphomas for mutations in the Notch1 gene using single strand conformation analysis (SSCA) and DNA sequencing. Genetic alterations resulting in premature truncation of Notch1 were identified in 28 tumors, whereas 8 revealed alterations in the heterodimerization and 16 harbored deletions in the ligand-binding region. Dideoxycytidine-induced lymphomas displayed the highest frequency of Notch1 mutations (49%), whereas in butadiene- and phenolphthalein-induced tumors showed lower frequencies (26 and 10%, respectively). In total, 26 novel and 3 previously reported mutations were detected. This report shows that Notch1 is a prevalent and major mutational target for 2′,3′-dideoxycytidine and butadiene-induced lymphoma. © 2008 Wiley-Liss, Inc.
References
- 1 Grabher C,von Boehmer H,Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev 2006; 6: 347–59.
- 2 Radtke F,Wilson A,Mancini SJ,MacDonald HR. Notch regulation of lymphocyte development and function. Nat Immunol 2004; 5: 247–53.
- 3 Logeat F,Bessia C,Brou C,LeBail O,Jarriault S,Seidah NG,Israel A. The Notch1 receptor is cleaved constitutively by a furin-like convertase. Proc Natl Acad Sci USA 1998; 95: 8108–12.
- 4 Rebay I,Fleming RJ,Fehon RG,Cherbas L,Cherbas P,Artavanis-Tsakonas S. Specific EGF repeats of Notch mediate interactions with delta and serrate: implications for notch as a multifunctional receptor. Cell 1991; 67: 687–99.
- 5 Sanchez-Irizarry C,Carpenter AC,Weng AP,Pear WS,Aster JC,Blacklow SC. Notch subunit heterodimerization and prevention of ligand-independent proteolytic activation depend, respectively, on a novel domain and the LNR repeats. Mol Cell Biol 2004; 24: 9265–73.
- 6 Brou C,Logeat F,Gupta N,Bessia C,LeBail O,Doedens JR,Cumano A,Roux P,Black RA,Israel A. A novel proteolytic cleavage involved in notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 2000; 5: 207–16.
- 7 De Strooper B,Annaert W,Cupers P,Saftig P,Craessaerts K,Mumm JS,Schroeter EH,Schrijvers V,Wolfe MS,Ray WJ,Goate A,Kopan R. A presenilin-1-dependent γ-secretase-like protease mediates release of notch intracellular domain. Nature 1999; 398: 518–22.
- 8 Rechsteiner M,Rogers SW. PEST sequences and regulation by proteolysis. Trends Biochem Sci 1996; 21: 267–71.
- 9 Gupta-Rossi N,Le Bail O,Gonen H,Brou C,Logeat F,Six E,Ciechanover A,Israel A. Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor. J Biol Chem 2001; 276: 34371–8.
- 10 Chiang MY,Xu ML,Histen G,Shestova O,Roy M,Nam Y,Blacklow SC,Sacks DB,Pear WS,Aster JC. Identification of a conserved negative regulatory sequence that influences the leukemogenic activity of NOTCH1. Mol Cell Biol 2006; 26: 6261–71.
- 11 Breit S,Stanulla M,Flohr T,Schrappe M,Ludwig WD,Tolle G,Happich M,Muckenthaler MU,Kulozik AE. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 2006; 108: 1151–7.
- 12 Lee SY,Kumano K,Masuda S,Hangaishi A,Takita J,Nakazaki K,Kurokawa M,Hayashi Y,Ogawa S,Chiba S. Mutations of the Notch1 gene in T-cell acute lymphoblastic leukemia: analysis in adults and children. Leukemia 2005; 19: 1841–3.
- 13 Lin YW,Nichols RA,Letterio JJ,Aplan PD. Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma. Blood 2006; 107: 2540–3.
- 14 Mansour MR,Linch DC,Foroni L,Goldstone AH,Gale RE. High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia. Leukemia 2006; 20: 537–9.
- 15 O'Neil J,Calvo J,McKenna K,Krishnamoorthy V,Aster JC,Bassing CH,Alt FW,Kelliher M,Look AT. Activating Notch1 mutations in mouse models of T-ALL. Blood 2006; 107: 781–5.
- 16 Shimizu D,Taki T,Utsunomiya A,Nakagawa H,Nomura K,Matsumoto Y,Nishida K,Horiike S,Taniwaki M. Detection of NOTCH1 mutations in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma. Int J Hematol 2007; 85: 212–18.
- 17 Weng AP,Ferrando AA,Lee W,Morris JPT,Silverman LB,Sanchez-Irizarry C,Blacklow SC,Look AT,Aster JC. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269–71.
- 18 Zhu YM,Zhao WL,Fu JF,Shi JY,Pan Q,Hu J,Gao XD,Chen B,Li JM,Xiong SM,Gu LJ,Tang JY, et al. NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis. Clin Cancer Res 2006; 12: 3043–9.
- 19 O'Neil J,Look AT. Mechanisms of transcription factor deregulation in lymphoid cell transformation. Oncogene 2007; 26: 6838–49.
- 20 Tsuji H,Ishii-Ohba H,Katsube T,Ukai H,Aizawa S,Doi M,Hioki K,Ogiu T. Involvement of illegitimate V(D)J recombination or microhomology-mediated nonhomologous end-joining in the formation of intragenic deletions of the Notch1 gene in mouse thymic lymphomas. Cancer Res 2004; 64: 8882–90.
- 21 Gatz SA,Wiesmuller L. p53 in recombination and repair. Cell Death Differ 2006; 13: 1003–16.
- 22 Malyukova A,Dohda T,von der Lehr N,Akhondi S,Corcoran M,Heyman M,Spruck C,Grander D,Lendahl U,Sangfelt O. The tumor suppressor gene hCDC4 is frequently mutated in human T-Cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res 2007; 67: 5611–16.
- 23 Maser RS,Choudhury B,Campbell PJ,Feng B,Wong KK,Protopopov A,O'Neil J,Gutierrez A,Ivanova E,Perna I,Lin E,Mani V, et al. Chromosomally unstable mouse tumors have genomic alterations similar to diverse human cancers. Nature 2007; 447: 966–71.
- 24 Rao GN,Collins BJ,Giles HD,Heath JE,Foley JF,May RD,Buckley LA. Carcinogenicity of 2′,3′-dideoxycytidine in mice. Cancer Res 1996; 56: 4666–72.
- 25 Melnick RL,Huff J,Chou BJ,Miller RA. Carcinogenicity of 1,3-butadiene in C57BL/6 × C3H F1 mice at low exposure concentrations. Cancer Res 1990; 50: 6592–9.
- 26 Dunnick JK,Hailey JR. Phenolphthalein exposure causes multiple carcinogenic effects in experimental model systems. Cancer Res 1996; 56: 4922–6.
- 27 Hulla JE,French JE,Dunnick JK. Chromosome 11 loss from thymic lymphomas induced in heterozygous Trp53 mice by phenolphthalein. Toxicol Sci 2001; 60: 264–70.
- 28 Zhuang SM,Eklund LK,Cochran C,Rao GN,Wiseman RW,Soderkvist P. Allelotype analysis of 2′,3′-dideoxycytidine- and 1,3-butadiene-induced lymphomas in B6C3F1 mice. Cancer Res 1996; 56: 3338–43.
- 29 Fischer A,Gessler M. δ-Notch–and then? Protein interactions and proposed modes of repression by Hes and Hey bHLH factors. Nucleic Acids Res 2007; 35: 4583–96.
- 30 Tsuji H,Ishii-Ohba H,Ukai H,Katsube T,Ogiu T. Radiation-induced deletions in the 5′ end region of Notch1 lead to the formation of truncated proteins and are involved in the development of mouse thymic lymphomas. Carcinogenesis 2003; 24: 1257–68.
- 31 Clevers HC,Grosschedl R. Transcriptional control of lymphoid development: lessons from gene targeting. Immunol Today 1996; 17: 336–43.
- 32 Beverly LJ,Capobianco AJ. Perturbation of Ikaros isoform selection by MLV integration is a cooperative event in Notch(IC)-induced T cell leukemogenesis. Cancer Cell 2003; 3: 551–64.
- 33 Dumortier A,Jeannet R,Kirstetter P,Kleinmann E,Sellars M,dos Santos NR,Thibault C,Barths J,Ghysdael J,Punt JA,Kastner P,Chan S. Notch activation is an early and critical event during T-Cell leukemogenesis in Ikaros-deficient mice. Mol Cell Biol 2006; 26: 209–20.
- 34 Tydell CC,David-Fung ES,Moore JE,Rowen L,Taghon T,Rothenberg EV. Molecular dissection of prethymic progenitor entry into the T lymphocyte developmental pathway. J Immunol 2007; 179: 421–38.
- 35 Karlsson A,Soderkvist P,Zhuang SM. Point mutations and deletions in the znfn1a1/ikaros gene in chemically induced murine lymphomas. Cancer Res 2002; 62: 2650–3.
- 36Beverly LJ,Felsher DW,Capobianco AJ.Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression.Cancer Res2005; 65: 7159–68.
- 37 Dalla-Favera R,Bregni M,Erikson J,Patterson D,Gallo RC,Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America 1982; 79: 7824–7.
- 38 Laws AM,Osborne BA. p53 regulates thymic Notch1 activation. Eur J Immunol 2004; 34: 726–34.
- 39 Lefort K,Mandinova A,Ostano P,Kolev V,Calpini V,Kolfschoten I,Devgan V,Lieb J,Raffoul W,Hohl D,Neel V,Garlick J, et al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev 2007; 21: 562–77.
- 40 Perez-Losada J,Mao JH,Balmain A. Control of genomic instability and epithelial tumor development by the p53-Fbxw7/Cdc4 pathway. Cancer Res 2005; 65: 6488–92.
- 41 Yugawa T,Handa K,Narisawa-Saito M,Ohno S,Fujita M,Kiyono T. Regulation of Notch1 gene expression by p53 in epithelial cells. Mol Cell Biol 2007; 27: 3732–42.